Table 4 Comparative analysis of the therapeutic effect of UCMSCs on the cumulative decrease in various parameters

AST

Group C

13 (− 10.5 to 40)

NS^CD

16 (− 20 to 57)

NS^CD

27 (− 1 to 77)

NS^CD

33.5 (9.5 to 85.2)

NS^CD

Group D

5 (0 to 27.5)

 − 1 (− 6 to 49.5)

5 (− 10.5 to 68)

1 (− 7 to 14.5)

Group B

22 (4 to 104.3)

NS^BD

4 (− 14 to 25)

NS^BD

17.5 (− 10.2 to 42)

NS^BD

2 (− 5 to 17.5)

0.004^BD

ALT

Group C

20 (− 3.5 to 153.5)

NS^CD

50 (7 to 172)

0.016^CD

35 (0 to 178)

NS^CD

54.5 (− 8 to 193)

NS^CD

Group D

7 (2 to 23.3)

6.5 (− 1.3 to 36)

9 (− 6.5 to 43.5)

2 (− 10 to 19.5)

Group B

32.5 (9.8 to335.5)

0.005^BD

45 (11 to 360.5)

0.004^BD

46 (11.5 to 358.8)

0.004^BD

49 (5 to 402)

0.002^BD

PTA

Group C

0.5 (− 6.5 to 6.8)

NS^CD

0.5 (− 8 to 9)

NS^CD

10.5 (− 0.5 to 27.8)

NS^CD

0.5 (− 28 to 29.8)

NS^CD

Group D

0.5 (− 5.3 to 4)

5.5 (− 4.5 to 14)

4 (− 3.8 to 10.5)

1 (− 3 to 14.5)

Group B

 − 1.5 (− 5.3 to 2)

NS^BD

2 (− 6 to 7)

NS^BD

5 (− 3 to 15)

NS^BD

1.5 (− 3 to 15.8)

NS^BD

MELD

Group C

0.5 (− 2 to 4)

NS^CD

 − 0.5 (− 2 to 4.3)

NS^CD

6.5 (2 to 1.5)

NS^CD

11 (8 to 12)

0.036^CD

Group D

1 (− 1 to 3)

3 (0.8 to 6)

1.5 (− 0.8 to 8.5)

3 (0 to 5.5)

Group B

0 (− 1 to 2)

NS^BD

4 (− 1.5 to 6)

NS^BD

4 (0.3 to 9.3)

NS^BD

3 (− 1 to 13)

NS^BD

AFP

Group C

32 (3 to 255)

0.021^CD

6 (− 2 to 41)

NS^CD

1 (− 9 to 59)

NS^CD

59 (1.5 to 339)

NS^CD

Group D

4.5 (1 to 27.8)

0 (− 1 to 3.5)

0 (0 to 22)

0.5 (− 0.8 to 21.8)

Group B

9 (1 to 85)

NS^BD

87 (− 8 to 185)

NS^BD

9 (− 2.5 to 165)

NS^BD

20 (0 to 188)

NS^BD